Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Stay Encouraging; Settlement Likely
Analyst John Newman noted that the stay on the injunction, pending the appeal, would allow the Regeneron/Sanofi SA (ADR) (NYSE:SNY) combine to continue selling Praluent beyond February 21 the original sales injunction date. The analyst termed the development is encouraging.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Canaccord Genuity expects a settlement with Amgen, which could call for paying a low-teens royalty on Praluent sales. The firm is of the view that Regeneron and Sanofi are unlikely to allow the appeal to produce a final court decision, given the loss of the litigation would lead to Praluent being taken off the market permanently.
Positive Data On Praluent Likely; Growth To Be Slow
The firm also thinks Amgen's Repatha CV outcomes presentation at the ACC between March 17 and 19 may elicit read through to Praluent, lifting sales. However, the firm believes doctors may prefer to wait for Praluent-specific outcomes data.
Additionally, PBMs may not make any changes to Praluent prior authorizations or step edits until positive outcomes data are available, the firm added. This, according to the firm, could favor easier access to Repatha in the interim. Although the firm believes Praluent will show positive outcomes data, helping in sales ramp up, it is of the view that Praluent growth will be slow, requiring multiple years to reach meaningful revenues.
FDA Vets Sanofi Plant
The firm also noted that the FDA has now deemed the Sanofi manufacturing plant acceptable for sarilumab and dupilumab manufacturing. If the on-site visit by FDA, planned for the first quarter of 2017, produces positive outcome, the firm thinks it would ensure on-track submission for sarilumab approval and dupilumab approval by the end of the first quarter of 2017.
Rating/Price Target
Canaccord Genuity has a Hold rating and a $450 price target for the shares of Regeneron. The Hold rating is predicated on several uncertainties:
- Negative data for Ang2 and EYLEA during the first half of 2017.
- Possibility of losing the appeal on the Praluent infringement litigation.
- Potentially higher percentage royalty that Regeneron and Sanofi would pay to Amgen.
- Possible unfavorable plant review by the FDA.
At Last Check
- Amgen was slipping 0.89 percent to $166.62.
- Regeneron was tacking on 1.48 percent to $358.47.
- Sanofi was gaining 3.49 percent to $42.65.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.